Pfizer, Inc. (PFE) Shares Sold by Bbva Compass Bancshares Inc.
Bbva Compass Bancshares Inc. lowered its holdings in Pfizer, Inc. (NYSE:PFE) by 1.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 411,355 shares of the biopharmaceutical company’s stock after selling 5,704 shares during the period. Pfizer comprises 0.9% of Bbva Compass Bancshares Inc.’s holdings, making the stock its 25th largest position. Bbva Compass Bancshares Inc.’s holdings in Pfizer were worth $13,818,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of PFE. D. Scott Neal Inc. boosted its position in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC purchased a new position in Pfizer in the first quarter worth $121,000. Cascade Investment Advisors Inc. boosted its position in Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 2,200 shares during the last quarter. Patten Group Inc. lifted its position in shares of Pfizer by 5.1% during the 1st quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock valued at $177,000 after buying an additional 252 shares during the last quarter. Finally, Acropolis Investment Management LLC lifted its position in shares of Pfizer by 6.7% during the 2nd quarter. Acropolis Investment Management LLC now owns 5,603 shares of the biopharmaceutical company’s stock valued at $188,000 after buying an additional 352 shares during the last quarter. 68.98% of the stock is currently owned by institutional investors and hedge funds.
Pfizer, Inc. (NYSE:PFE) opened at 36.24 on Friday. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $36.60. The company has a market capitalization of $215.53 billion, a price-to-earnings ratio of 26.51 and a beta of 1.00. The firm has a 50-day moving average price of $35.49 and a 200-day moving average price of $33.82.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the previous year, the business earned $0.64 earnings per share. The business’s revenue was down 1.9% on a year-over-year basis. Analysts anticipate that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be given a $0.32 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.53%. Pfizer’s payout ratio is 94.12%.
A number of brokerages have recently commented on PFE. Jefferies Group LLC set a $35.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Wednesday, August 2nd. BMO Capital Markets reaffirmed a “buy” rating and set a $39.00 price target (up previously from $37.00) on shares of Pfizer in a research report on Thursday. Berenberg Bank set a $39.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Tuesday, August 1st. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research report on Tuesday, October 3rd. Finally, Cowen and Company set a $43.00 price target on Pfizer and gave the company a “buy” rating in a research report on Monday, August 14th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $38.26.
In other news, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the transaction, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock worth $15,813,961 over the last 90 days. Company insiders own 0.06% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.